• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Levicept Appoints Eliot Forster as CEO

    11/30/23 4:00:00 AM ET
    $IMCR
    $IMTX
    $PLX
    $FSTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $IMCR alert in real time by email

    Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances

    SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO.

    Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matures through clinical development of LEVI-04 towards the future advancement and its ultimate commercialisation.

    LEVI-04 modulates the neurotrophin pathway, that is clinically proven to provide effective analgesia in a range of indications and is designed to minimise use-limiting side effects of anti-NGF antibodies, including rapid progression of osteoarthritis. Having successfully completed a phase I trial in 2021, Levicept is advancing LEVI-04, a proprietary p75 neurotrophin receptor fusion protein (p75NTR-Fc), a once-a-month injectable for the treatment of osteoarthritis and chronic pain, through a 500+ patient phase II clinical trial.

    Eliot was most recently CEO of F-star (NASDAQ:FSTX), a clinical-stage, NASDAQ-listed biotech that was acquired by inovX Pharma limited in March 2023. Prior to this he was CEO of Immunocore (NASDAQ:IMCR), and previously led the clinical development of several pain medicines, including the COX-2 inhibitors. His early career was at GSK and Pfizer. Alongside his role at Levicept, currently he serves on the Boards of Tessellate BIO, Avacta Group (AIM:AVCT), Ochre Bio, Protalix Biotherapeutics (AMEX:PLX), and Immatics NV (NASDAQ:IMTX).

    Eliot Forster, CEO of Levicept, said, "The safe and effective management of chronic pain remains a critical need in medicine. While existing treatments can be effective, their use is often limited by adverse effects, addiction-liabilities, or poor pain control. LEVI-04 has the potential to effectively target the clinically proven neurotrophin pain pathways, but with a superior safety profile. I very much look forward to working with Simon and his team to advance this important programme to its completion."

    Kevin Johnson, Chairman of Levicept and Partner at investor Medicxi, said, "As a highly focused single-asset company, Levicept has made excellent progress with LEVI-04 though phase I and ongoing phase II studies. With data to date looking very promising, I am delighted to welcome Eliot to the company at an important time for the company, to work with Simon and the team to help steer the best path for the further development of LEVI-04."

    Simon Westbrook, founder and CSO of Levicept, said, "Eliot's appointment underlines the potential we see in LEVI-04 and the near-term opportunities on the back of the pre-clinical and clinical work we have undertaken. With our phase II trial nearing completion, we can now benefit from Eliot's experience and networks to ultimately maximise the chances of LEVI-04 reaching patients and offering a new, safe treatment for chronic pain."

    It is estimated that the market opportunity for drugs that modulate neurotrophins, developed to a high safety standard, will be worth in excess of $10 billion by 2033.

    Levicept

    Eliot Forster, CEO – [email protected]

    Media Enquiries

    Charles Consultants

    Sue Charles – [email protected] +44 (0)7968 726585

    Chris Gardner - [email protected] +44 (0)7956 031077

    About Levicept – www.levicept.com

    Levicept Ltd is a UK-based biotechnology company developing a novel, safe and efficacious biological therapy (LEVI-04 [p75NTR-Fc]) for the treatment of chronic pain. LEVI-04 is currently in phase II in patients with osteoarthritis of the knee. LEVI-04 modulates the neurotrophin pathway, clinically proven to provide effective analgesia in a range of indications and is designed to minimise use-limiting side effects of anti-NGF antibodies, including rapid progression of osteoarthritis. It is estimated that the market opportunity for drugs that modulate neurotrophins, developed to a high safety standard, will be worth in excess of $10 billion by 2033. LEVI-04 was originally discovered at Pfizer by Levicept's founder, Simon Westbrook who subsequently acquired the asset. Levicept's investors include Medicxi, Advent Life Sciences, Gilde Healthcare and Pfizer Ventures.

    Follow us on LinkedIn - https://www.linkedin.com/company/levicept-ltd



    Primary Logo

    Get the next $IMCR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMCR
    $IMTX
    $PLX
    $FSTX

    CompanyDatePrice TargetRatingAnalyst
    Immunocore Holdings plc
    $IMCR
    12/13/2024$74.00 → $35.00Overweight → Equal-Weight
    Morgan Stanley
    Immunocore Holdings plc
    $IMCR
    11/11/2024$72.00 → $38.00Outperform → Neutral
    Mizuho
    Immunocore Holdings plc
    $IMCR
    10/24/2024$24.00Sell
    UBS
    Immunocore Holdings plc
    $IMCR
    10/7/2024Buy → Neutral
    Guggenheim
    Immatics N.V.
    $IMTX
    10/7/2024$19.00Overweight
    Piper Sandler
    Immunocore Holdings plc
    $IMCR
    4/29/2024$74.00Outperform
    Leerink Partners
    Immunocore Holdings plc
    $IMCR
    11/20/2023$60.00Overweight
    JP Morgan
    Immunocore Holdings plc
    $IMCR
    11/2/2023Overweight
    Cantor Fitzgerald
    More analyst ratings

    $IMCR
    $IMTX
    $PLX
    $FSTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

      Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2025, and provided a business and clinical update. "We had another solid quarter, with an increase in revenues from selling goods compared to the prior year quarter," said Dror Bashan, Protalix's President and Chief Executive Officer. "Given the promising resul

      5/9/25 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore reports first quarter financial results and provides a business update

      Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities of $837 million as of March 31, 2025 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, May 7, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Com

      5/7/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

      Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, May 5, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2025 and provide a business and clinical update on May 9, 2025. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Details: Date:   

      5/5/25 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    $IMTX
    $PLX
    $FSTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Baker Bros. Advisors Lp bought $23,993,224 worth of American Depositary Shares (807,338 units at $29.72) (SEC Form 4)

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      3/19/25 6:40:21 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Pao William

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      2/27/25 4:31:08 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Pao William

      3 - Immunocore Holdings plc (0001671927) (Issuer)

      2/27/25 4:29:34 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    $IMTX
    $PLX
    $FSTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development

      Immunocore appoints Travis Coy, previously a Non-Executive Director, as its EVP, Chief Financial Officer and Head of Corporate Development (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, 02 January 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announces that Travis Coy has been appointed as Executive Vice President (EVP), Chief Financial Officer and Head of Corporate Development, effective January 1, 2025. He will become an Exe

      1/2/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immatics Appoints Alise Reicin to Board of Directors

      Houston, Texas and Tuebingen, Germany, July 31, 2024 – Immatics N.V. (NASDAQ:IMTX, "Immatics" or the "Company"))), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced the appointment of Alise Reicin, M.D., to its Board of Directors. Alise Reicin is an experienced and expert pharmaceutical industry executive and leader who has led the development of multiple important new therapies, including Keytruda®. Dr. Reicin currently serves as the President and CEO of Tectonic Therapeutic and is also a member of the Board of Directors of Sana Biotechnology. She joins Immatics' Board of Directors as the Company

      7/31/24 7:00:00 AM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors

      Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e

      7/8/24 8:15:00 AM ET
      $PIRS
      $TTOO
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments

    $IMCR
    $IMTX
    $PLX
    $FSTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

      SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

      11/14/24 1:28:34 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Immatics N.V.

      SC 13G - Immatics N.V. (0001809196) (Subject)

      11/14/24 1:28:33 PM ET
      $IMTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Immunocore Holdings plc

      SC 13G/A - Immunocore Holdings plc (0001671927) (Subject)

      11/14/24 1:22:39 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    $IMTX
    $PLX
    $FSTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Baker Bros. Advisors Lp bought $23,993,224 worth of American Depositary Shares (807,338 units at $29.72) (SEC Form 4)

      4 - Immunocore Holdings plc (0001671927) (Issuer)

      3/19/25 6:40:21 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Bashan Dror bought $90,484 worth of shares (64,516 units at $1.40), increasing direct ownership by 95% to 132,516 units (SEC Form 4)

      4 - Protalix BioTherapeutics, Inc. (0001006281) (Issuer)

      10/20/23 6:50:07 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    $IMTX
    $PLX
    $FSTX
    Financials

    Live finance-specific insights

    See more
    • Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

      Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, May 9, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2025, and provided a business and clinical update. "We had another solid quarter, with an increase in revenues from selling goods compared to the prior year quarter," said Dror Bashan, Protalix's President and Chief Executive Officer. "Given the promising resul

      5/9/25 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore reports first quarter financial results and provides a business update

      Immunocore reports first quarter financial results and provides a business update KIMMTRAK® (tebentafusp-tebn) net revenues of $93.9 million in Q1 2025, growing by 33% year-over-year On track for Phase 3 TEBE-AM trial to complete enrollment in 1H 2026 On track for dose selection in Phase 3 PRISM-MEL-301 trial in 2H 2025 Initial multiple ascending dose data for HIV functional cure candidate presented during oral session at CROI 2025; dose escalation ongoing Cash, cash equivalents and marketable securities of $837 million as of March 31, 2025 (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, May 7, 2025) Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Com

      5/7/25 7:00:00 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

      Company to host conference call and webcast at 8:30 a.m. EDT CARMIEL, Israel, May 5, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2025 and provide a business and clinical update on May 9, 2025. Management will host a conference call to discuss the financial results and provide an update on recent corporate and regulatory developments. Conference Call Details: Date:   

      5/5/25 6:50:00 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    $IMTX
    $PLX
    $FSTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Immunocore downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Immunocore from Overweight to Equal-Weight and set a new price target of $35.00 from $74.00 previously

      12/13/24 8:04:38 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Immunocore downgraded by Mizuho with a new price target

      Mizuho downgraded Immunocore from Outperform to Neutral and set a new price target of $38.00 from $72.00 previously

      11/11/24 7:41:04 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • UBS initiated coverage on Immunocore with a new price target

      UBS initiated coverage of Immunocore with a rating of Sell and set a new price target of $24.00

      10/24/24 6:22:17 AM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $IMCR
    $IMTX
    $PLX
    $FSTX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Protalix BioTherapeutics Inc. (DE)

      10-Q - Protalix BioTherapeutics, Inc. (0001006281) (Filer)

      5/9/25 7:04:04 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Protalix BioTherapeutics Inc. (DE) filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Protalix BioTherapeutics, Inc. (0001006281) (Filer)

      5/9/25 6:57:27 AM ET
      $PLX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form S-8 filed by Immunocore Holdings plc

      S-8 - Immunocore Holdings plc (0001671927) (Filer)

      5/7/25 4:38:41 PM ET
      $IMCR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care